** Shares of Chinese pharmaceutical products developer Ascletis Pharma Inc 1672.HK jump 8.7% to HK$7.99, their highest since March 2019
** Stock on course for the biggest one-day gain since March 3; on track for third straight session of rise
** Ascletis announces positive topline results of Phase 1B studies of weight loss drug candidate ASC47 monotherapy in Australia
** Says U.S. Food and Drug Administration has cleared the U.S. Investigational New Drug application for ASC47 in combination with semaglutide for the treatment of obesity
** Hong Kong's healthcare index .HSCIH and Hang Seng Index .HSI both slip 0.1%
** Stock up 144.2% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.